Introduction
============

The establishment of health-based guidance values is a key outcome of assessing the risk of chemical agents. The determination of such values includes the derivation of a point of departure (POD) from dose--response modeling or, more traditionally, use of the no-observed-adverse-effect-level (NOAEL). Dose--response modeling approaches, specifically the benchmark dose (BMD) method, are generally regarded by many international health organizations as the method of choice for derivation of the POD \[[@r7]; [@r10]\].

For nongenotoxic agents, uncertainty factors accounting for inter- and intra-species differences are applied to the POD derived from the critical effect observed in animals or humans ([@r9]). This results in a health-based guidance value, such as a tolerable daily intake (TDI), an acceptable daily intake (ADI), a reference dose (RfD), or a reference concentration (RfC). Although the exact formulation of the TDI/ADI \[[@r35]\] differs to some extent from that for the RfD/RfC, these quantities are derived in essentially the same manner and can thus be interpreted similarly. The TDI/ADI/RfD is generally set for dietary exposure, whereas the RfC is generally set for occupational exposures occurring via inhalation; an extensive discussion of occupational exposure limits can be found in [@r8].

In the case of a genotoxic agent, the U.S. EPA risk-assessment guidelines recommend low-dose linear extrapolation when *a*) there are data to indicate that the dose--response curve has a linear component below the POD, or *b*) as a default for a tumor site where the mode of action is not established ([@r31]). Linear extrapolation to low doses permits upper-bound estimates of risk at exposure levels of interest as well as estimation of "risk-specific doses" associated with specific (upper-bound) risk levels; the typical U.S. EPA target range for risk management is a 1/1,000,000 to 1/10,000 increased lifetime risk ([@r31]). In contrast, both the European Food Safety Authority (EFSA) and the Joint FAO (Food and Agriculture Organization of the United Nations)/WHO Expert Committee on Food Additives (JECFA) have recommended a margin of exposure (MOE) approach rather than low-dose linear extrapolation for evaluating compounds that are both genotoxic and carcinogenic. EFSA and the JECFA considered that the MOE had the potential to help risk managers to distinguish between large, intermediate, and low health concerns, and thus to provide guidance for setting priorities for risk management actions ([@r2]). The MOE is also cited in the U.S. EPA guidelines but is positioned as a quantity that provides an indication of the extent of extrapolation of risk estimates from the observed data to the exposure levels of interest in practice ([@r31]).

Traditional approaches to risk assessment, including the establishment of health-based guidance values based on the results of mammalian toxicology tests, have been challenged by the U.S. National Research Council (NRC) in its report, *Toxicity Testing in the 21st Century: A Vision and a Strategy* ([@r19]). This report envisions that future toxicity tests will be conducted largely in human cells or cell lines *in vitro* by evaluating cellular responses in a suite of toxicity pathway assays using high-throughput tests. Risk assessments would be performed based on the results of such tests, and the equivalents of today's health-based guidance values would aim, according to the NRC, at representing dose levels that avoid significant perturbations of the toxicity pathways in exposed human populations. *In vitro* to *in vivo* extrapolations would rely on pharmacokinetic models to predict human blood and tissue concentrations under specific exposure conditions ([@r1]; [@r15], [@r16]; [@r19]). The NRC vision for the future of toxicity testing has recently been incorporated into the U.S. EPA's framework for the next generation of risk science ([@r17]).

In line with this vision, [@r14] presented a framework for estimating the human dose at which a chemical significantly alters biological pathways *in vivo*, making use of *in vitro* assay data and an *in vitro*--derived pharmacokinetic model, along with information on population variability and uncertainty. [@r14] calculated a "biological pathway altering dose" (BPAD), which they regarded as conceptually analogous to current risk-assessment metrics in that it combines dose--response data with analysis of uncertainty and population variability to arrive at conservative human exposure limits. Further discussion is needed on how a "biological significant perturbation," and hence the BPAD, or related metric, should be defined. At a general level, in response to the [@r19], [@r6] considered four possible definitions that were all regarded to incorporate the notion of an exposure threshold for apical response. At a more detailed level, this problem formulation may also concern the technical definition of the POD from a statistical standpoint, which is the focus of the present paper.

Historically, several approaches have been presented in the scientific literature on how to define the BMD and its lower confidence limit (BMDL) ([@r5]; [@r18]; [@r24], [@r23], [@r20]; [@r27]). In their opinion on the BMD, EFSA recommended a default setting for implementation of the BMD approach: in the case of quantal data, they recommended that the BMD by default be defined as the dose corresponding to an extra risk of 10%, and for continuous (experimental) data, they recommended that the BMD by default be defined as corresponding to a 5% change in response relative to the mean background response ([@r10]). The guidance provided by the U.S. EPA is similar to that issued by EFSA for quantal data, but the default approaches for continuous data differ between the two agencies ([@r7]).

[@r20] introduced the concept of the signal-to-noise crossover dose (SNCD) as an objective approach to determine the lowest dose applicable as a POD, such that its corresponding effect is not overwhelmed by biological noise or uncertainty in the data. Specifically, the SNCD is defined as the dose at which the ratio between the additional effect (the "signal") and the difference between the upper and lower bounds of the two-sided 90% confidence interval on absolute effect (the "noise") correspond to some critical value (critical signal-to-noise ratios of 1, 0.67, and 0.5 are used in the present study). [@r20] compared BMDLs and NOAELs to the SNCD, using values derived from fitting concentration--response data from the U.S. National Toxicology Program (NTP) carcinogenesis bioassay database. The NTP cancer studies represent one of the types of toxicity data that are currently used as a basis for risk assessment. Motivated by the anticipated shift towards the use of *in vitro* rather than whole-animal bioassay data as the basis for risk assessment, the present study extended the comparison of different BMDLs with the SNCD to the case of high-throughput *in vitro* screening data. Using the SNCD as a statistical reference point, this study aimed to provide insights into how low response levels in general may be associated with BMDs based on HTS data; the role of the SNCD as a starting point for low-dose extrapolation is also discussed. The analysis performed was based on \> 10,000 *in vitro* concentration--response curves generated on \> 1,400 compounds as part of the U.S. Tox21 Phase I effort ([@r30]).

Materials and Methods
=====================

Dose--Response Data
-------------------

The Tox21 program ([@r30]) is a collaboration between U.S. federal health research agencies for the purpose of developing and applying new methods for chemical toxicity testing. Phase I of the Tox21 program tested \~2,800 chemicals, half of which were chosen by the NTP and half of which were chosen by the U.S. EPA. The chemicals were tested in \> 50 high-throughput screening assays. Data from the Tox21 Phase I assays consist of 14- or 15- point concentration--response curves. Analysis of compound concentration--response data was performed as described ([@r13]). Briefly, raw 1,536-well plate reads for each titration point were first normalized relative to the assay-specific positive control compound (100%) and dimethyl sulforxide (DMSO)-only wells (basal, 0%) on the same 1,536-well plate and then were corrected by applying a pattern correction algorithm using the compound-free 1,536-well control plates (i.e., DMSO-only plates) at the beginning and end of the compound plate stack.

Data Selection
--------------

The assays in Phase I of Tox21 include several types of end points ([@r30]). This analysis includes three groups of assays: cytotoxicity assays, nuclear receptor assays, and assays for stress response pathways. Data sets included in this analysis are listed in [Table 1](#t1){ref-type="table"}. Most of these data are available in the PubChem BioAssay database ([@r32]). Each data set represents one run of an assay on one set of chemicals (U.S. EPA or NTP chemicals). Some assays were run more than once on the same chemical, or in different cell lines, or with multiple end points; those are listed as separate data sets in the table. The analysis included 47 nuclear receptor assay data sets, 23 cytotoxicity assay data sets, and 12 stress response assay data sets.

###### 

Data sets used in the analysis.

  Assay                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            PubChem BioAssay ID (AID)   Chemical source   Number of concentration--response curves in Classes 1 and 2^*a*^
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ----------------- ------------------------------------------------------------------
  Nuclear receptor assays                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Human androgen receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  588515                      EPA               114
  Human androgen receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               588516                      EPA               289
  Human estrogen α receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                588514                      EPA               230
  Human estrogen α receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         EPA               429
  Human farnesoid X receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               588527                      EPA               20
  Human farnesoid X receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            588526                      EPA               199
  Human glucocorticoid receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            588532                      EPA               15
  Human glucocorticoid receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         588533                      EPA               154
  Human peroxisome proliferator-activated receptor γ agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       588536                      EPA               181
  Human peroxisome proliferator-activated receptor γ antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    588537                      EPA               206
  Human peroxisome proliferator-activated receptor δ agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       588534                      EPA               106
  Human peroxisome proliferator-activated receptor δ antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    588535                      EPA               159
  Human retinoid X receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                588544                      EPA               337
  Human retinoid X receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             588546                      EPA               245
  Human thyroid receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   588545                      EPA               41
  Human thyroid receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                588547                      EPA               98
  Human vitamin D receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 588543                      EPA               24
  Human vitamin D receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              588541                      EPA               120
  Human androgen receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  588515                      NTP               146
  Human androgen receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               588516                      NTP               367
  Human aryl hydrocarbon receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          651777                      NTP               86
  Human estrogen α receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                588514                      NTP               157
  Human estrogen α receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             588513                      NTP               139
  Human farnesoid X receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               588527                      NTP               9
  Human farnesoid X receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            588526                      NTP               211
  Human glucocorticoid receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            588532                      NTP               14
  Human glucocorticoid receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         588533                      NTP               189
  Human peroxisome proliferator-activated receptor α agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       651778                      NTP               13
  Human peroxisome proliferator-activated receptor α antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    NA                          NTP               227
  Human peroxisome proliferator-activated receptor α antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    NA                          NTP               237
  Human peroxisome proliferator-activated receptor γ agonist, CHO cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            NA                          NTP               16
  Human peroxisome proliferator-activated receptor γ agonist, CHO cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            NA                          NTP               31
  Human peroxisome proliferator-activated receptor γ agonist, Hek293 cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         588536                      NTP               77
  Human peroxisome proliferator-activated receptor γ antagonist, Hek293 cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      588537                      NTP               232
  Human peroxisome proliferator-activated receptor δ agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       588534                      NTP               110
  Human peroxisome proliferator-activated receptor δ antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    588535                      NTP               245
  Human pregnane X receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                720659                      NTP               192
  Human retinoid X receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                588544                      NTP               177
  Human retinoid X receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             588546                      NTP               97
  Human thyroid receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   588545                      NTP               89
  Human thyroid receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                588547                      NTP               67
  Human vitamin D receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 588543                      NTP               16
  Human vitamin D receptor antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              588541                      NTP               94
  Rat pregnane X receptor agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  651751                      NTP               153
  Cytotoxicity assays                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Viability in 3T3 cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           NA                          NTP               236
  Viability in BJ cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            421                         NTP               80
  Viability in endotoxin assay                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NA                          NTP               334
  Viability in glucocorticoid receptor assay                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       NA                          NTP               111
  Viability in H-4-II-E cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      543                         NTP               231
  Viability in Hek293 cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        131                         NTP               131
  Viability in HeLa cells in the antioxidant response element assay                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                NA                          NTP               111
  Viability in HepG2 cells in the antioxidant response element assay                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               720653                      NTP               62
  Viability in HepG2 cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         433                         NTP               156
  Viability in HepG2 cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NA                          NTP               189
  Viability in HepG2 cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NA                          NTP               173
  Viability in HUVEC cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         542                         NTP               110
  Viability in Jurkat cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        426                         NTP               213
  Viability in mesangial cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     546                         NTP               108
  Viability in mesangial cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NA                          NTP               51
  Viability in MRC-5 cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         434                         NTP               73
  Viability in N2a cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           540                         NTP               202
  Viability in nuclear factor κB assay                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             NA                          NTP               27
  Viability in p53 assay                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           743292                      NTP               69
  Viability in peroxisome proliferator-activated receptor α assay                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  NA                          NTP               95
  Viability in rat renal proximal tubule cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     545                         NTP               159
  Viability in SH-SY5Y cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       544                         NTP               244
  Viability in SK-N-SH cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       435                         NTP               126
  Stress response assays                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Antioxidant response element, beta-lactamase reporter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            651741                      NTP               583
  Antioxidant response element, luciferase reporter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                720636                      NTP               192
  Cyclic AMP response element agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              NA                          NTP               162
  Cyclic AMP response element antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           NA                          NTP               139
  Endoplasmic reticulum stress response element                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    NA                          NTP               51
  Heat shock protein, luciferase reporter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NA                          NTP               7
  Heat shock protein, luciferase reporter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NA                          NTP               31
  Heat shock protein, beta-lactamase reporter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NA                          NTP               24
  Hypoxia inducible factor 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       2120                        NTP               73
  Nuclear factor κB agonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        651749                      NTP               26
  Nuclear factor κB antagonist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NA                          NTP               231
  p53 gene                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         651743                      NTP               72
  Notes: EPA, U.S. Environmental Protection Agency; NA, not available on PubChem; NTP, National Toxicology Program. ^***a***^Each concentration--response curve has a curve classification, based on the fit of a Hill equation to the curve (Xia et al. 2011; Huang et al. 2011). For this analysis, only curves in classes 1 and 2 ("complete response curve" and "incomplete curve," respectively) were used because the other curve classes indicate the lack of a concentration response or show significant activity only at the highest concentration and are therefore problematic for the purpose of fitting a sigmoidal (four-parameter) model such as the Hill model.                                                 

In addition to the concentration and response data, each concentration--response curve has a curve classification based on the fit of a Hill equation to the curve ([@r36]; [@r12]). There have been two slightly different systems of curve classification. When the more recent curve classification ([@r12]) became available, it was used; otherwise, the classification from the older system was used ([@r36]). For this analysis, only curves in classes 1 and 2 ("complete response curve" and "incomplete curve," respectively) were used because the other curve classes indicate the lack of a concentration response or show significant activity only at the highest concentration and are therefore problematic for the purpose of fitting a sigmoidal (four parameter) model, such as the Hill model. Thus, the present work was limited to address POD derivation for concentration--response curves that are fairly well characterized, as in the previous study using this method ([@r20]). The assays include replicated data for some of the study chemicals. The present analysis in this paper does not take replication into account, that is to say, replicates were considered as separate concentration--response curves; however, an extended analysis focusing on NTP duplicates was also performed. The number of concentration--response curves used from each data set is given in [Table 1](#t1){ref-type="table"}. The data normalization and curve classification process includes outlier determination. Outlier points, as specified in the data obtained from Tox21, were not included in the fitting of the Hill function to the data.

Dose--Response Modeling and Estimation of PODs
----------------------------------------------

Dose--response modeling was performed using the Hill model fit to the data by maximum likelihood, with a parametric bootstrap approach for obtaining confidence limits on the PODs derived from the fitted model. The 11,240 concentration--response curves included as a starting point in the analysis were modeled using an automated protocol developed in Matlab (The MathWorks, Inc.). The details associated with the model-fitting approach and POD estimation can be found in "Concentration--response modeling and estimation of PODs" in the Supplemental Material. The quantities described below were estimated for each curve.

1.  The BMD, with a two-sided 90% confidence interval, corresponding to extra effects of 5%, 10%, 20%, 30%, and 40%. The extra effect is defined as a percent change in response relative to the estimated range of response. A subscript "e" is used to denote these BMDs (e.g., BMD~e~, BMDL~e~, BMD~10e~, BMDL~10e~).

2.  The BMD, with a two-sided 90% confidence interval, corresponding to additional effects of 5%, 10%, 15%, 20%, and 25%. The additional effect is defined as an absolute change in response compared to the estimated background response. A subscript "a" is used to denote these BMDs (e.g., BMD~a~, BMDL~a~, BMD~10a~, BMDL~10a~).

3.  The SNCD corresponding to signal-to-noise ratios of 1.0, 0.67, and 0.5, denoted by SNCD~1.0~, SNCD~0.67~, and SNCD~0.5~, respectively. The point estimate, as well as the upper 95th confidence bound, for the effect (under both the additional and extra effect definitions) at concentrations corresponding to each of the three SNCDs was also derived.

The three types of POD approaches (BMD~e~, BMD~a~, and SNCD) are illustrated in [Figure 1](#f1){ref-type="fig"}. Additionally, a discussion of the BMD and SNCD definitions, including why the applied BMD definitions were preferred over the definition suggested for continuous data by [@r10], is provided in "Definition of the SNCD and the BMD" in the Supplemental Material.

![Illustration of the three types of point-of-departure (POD) approaches considered in the study. Nuclear receptor assay concentration response data on pimozide is used as an example (solid circles). The Hill model has been fitted to the data: in all three cases, the solid curves that describe the mean response are the same, but the two-sided 90% confidence intervals around the mean response (the dotted curves) depend on the POD approach considered. (*A*) The benchmark dose (BMD) associated with a 10% extra effect (BMD~10e~) is 0.24 units (solid red vertical line), and the lower 5th and upper 95th confidence limits (vertical dotted lines) are 0.15 (BMDL~10e~) and 0.37 units, respectively. (*B*) The BMD associated with a 10% additional effect (BMD~10a~) is 0.28 units (solid red vertical line), and the lower 5th and upper 95th confidence limits (vertical dotted lines) are 0.18 (BMDL~10a~) and 0.42 units, respectively. (*C*) The SNCD~1.0~ associated with a signal-to-noise ratio (SNR) of 1.0 is 0.31 units (solid red vertical line). The difference between the lower and upper bounds on absolute effect at the SNCD is ≈ 10.4 -- (--1.2) = 11.6 (difference between the horizontal dotted lines). Because the SNR is 1.0, this approximates to the point estimate of additional effect at the signal-to-noise crossover dose (SNCD), which is ≈ 4.6 -- (--7.0) = 11.6 (difference between the horizontal solid line and the background response according to the fitted model). In this example, SNCD~1.0~ is approximately twice the size of the BMDLs.](EHP408.g001){#f1}

Comparison of PODs
------------------

BMDLs were compared to the SNCD (specifically, SNCD~1.0~, SNCD~0.67~, and SNCD~0.5~). These comparisons were based on curves for which all estimated BMDs and SNCDs (in total, 10 BMDs and 3 SNCDs) were within the experimental concentration range (*n* = 8,961). In addition, results associated with nonsignificant concentration--response curves (*n* = 192) and curves for which the estimated maximum response was \> 150 or \< --150 (*n* = 313 additional curves) were excluded. These combined criteria reduced the 11,240 curves by 25% to 8,456 curves for inclusion in the present study. As noted previously, details of the model-fitting approach and POD estimation can be found in "Concentration--response modeling and estimation of PODs" in the Supplemental Material.

Results
=======

BMDLs Based on Extra Effect versus the SNCD
-------------------------------------------

Considering all curves selected for inclusion (*n* = 8,456), the BMDL~40e~ calibrated to the SNCD~1.0~ at the median ([Figure 2A](#f2){ref-type="fig"}). A concentration between the BMDL~20e~ and the BMDL~30e~ corresponded to the SNCD~1.0~ for stress response assays; the BMDL~30e~ calibrated to the SNCD~1.0~ for cytotoxicity assays; and all BMDLs were below the SNCD~1.0~ at the median for nuclear receptor assays ([Figure 2A](#f2){ref-type="fig"}).

![Ratios of the BMDL~e~ to the SNCD with BMDLs defined in terms of extra effects of 5%, 10%, 20%, 30%, and 40%. Ratios are given in terms of medians (solid circles) and intervals describing the lower 5th and upper 95th percentiles, based on different stratifications of the data. Red (large) circles correspond to results based on all selected curves (*n *= 8,456); blue circles correspond to results based on cytotoxicity assays (*n *= 3,130); yellow circles correspond to results based on nuclear receptor assays (*n *= 4,603); and cyan circles are results based on stress response assays (*n *= 723). (*A*) Ratios of the BMDL~e~ to the SNCD~1.0~. (*B*) Ratios of the BMDL~e~ to the SNCD~0.67~. (*C*) Ratios of the BMDL~e~ to the SNCD~0.5~. BMDL, lower confidence limit of the benchmark dose; SNCD, signal-to-noise crossover dose.](EHP408.g002){#f2}

A concentration level between the BMDL~20e~ and the BMDL~30e~ corresponded to the SNCD~0.67~, at the median, across all *n* = 8,456 curves ([Figure 2B](#f2){ref-type="fig"}). A concentration between the BMDL~10e~ and the BMDL~20e~ corresponded to the SNCD~0.67~ for stress response assays; the BMDL~20e~ calibrated to the SNCD~0.67~ for cytotoxicity assays; and a concentration between the BMDL~30e~ and the BMDL~40e~ corresponded to the SNCD~0.67~ for nuclear receptor assays ([Figure 2B](#f2){ref-type="fig"}). Histograms for the ratios BMDL:SNCD~0.67~ with medians closest to 1 are shown in [Figure 3](#f3){ref-type="fig"} (considering all *n* = 8,456 curves).

![Histograms for the ratios BMDL~e~:SNCD~0.67~ (BMDLs are based on extra effect) with medians closest to 1 based on all included curves (*n *= 8,456). BMDL, lower confidence limit of the benchmark dose; SNCD, signal-to-noise crossover dose.](EHP408.g003){#f3}

At the median, the BMDL~20e~ was closest to the SNCD~0.5~ when all 8,456 curves were considered ([Figure 2C](#f2){ref-type="fig"}). The BMDL~10e~ calibrated to the SNCD~0.5~ for stress response assays; the BMDL~10e~ was closest to the SNCD~0.5~ for cytotoxicity assays; and a concentration between the BMDL~20e~ and the BMDL~30e~ corresponded to the SNCD~0.5~ for nuclear receptor assays ([Figure 2C](#f2){ref-type="fig"}).

BMDLs Based on Additional Effect versus the SNCD
------------------------------------------------

Considering all included curves (*n* = 8,456), the BMDL~25a~ calibrated to the SNCD~1.0~ at the median ([Figure 4A](#f4){ref-type="fig"}). The BMDL~15a~ calibrated to the SNCD~1.0~ for stress response assays; a concentration between the BMDL~20a~ and the BMDL~25a~ corresponded to the SNCD~1.0~ for cytotoxicity assays; and all BMDLs were below the SNCD~1.0~ at the median for nuclear receptor assays ([Figure 4A](#f4){ref-type="fig"}).

![Ratios of the BMDL~a~ to the SNCD with BMDLs defined in terms of additional effects of 5%, 10%, 15%, 20%, and 25%. Ratios are given in terms of medians (solid circles) and intervals describing the lower 5th and upper 95th percentiles, based on different stratifications of the data. Red (large) circles correspond to results based on all selected curves (*n *= 8,456); blue circles correspond to results based on cytotoxicity assays (*n *= 3,130); yellow circles correspond to results based on nuclear receptor assays (*n *= 4,603); and cyan circles are results based on stress response assays (*n *= 723). (*A*) Ratios of the BMDL~a~ to the SNCD~1.0~. (*B*) Ratios of the BMDL~a~ to the SNCD~0.67~. (*C*) Ratios of the BMDL~a~ to the SNCD~0.5~. BMDL, lower confidence limit of the benchmark dose; SNCD, signal-to-noise crossover dose.](EHP408.g004){#f4}

At the median, the SNCD~0.67~ lay between the BMDL~15a~ and the BMDL~20a~ for all curves (*n* = 8,456) ([Figure 4B](#f4){ref-type="fig"}). The BMDL~10a~ was closest to the SNCD~0.67~ for stress response assays; the BMDL~15a~ calibrated to the SNCD~0.67~ for cytotoxicity assays; and a concentration between the BMDL~20a~ and the BMDL~25a~ corresponded to the SNCD~0.67~ for nuclear receptor assays ([Figure 4B](#f4){ref-type="fig"}). Histograms for the ratios BMD:SNCD~0.67~ with medians closest to 1 are shown in [Figure 5](#f5){ref-type="fig"} (considering all *n* = 8,456 curves).

![Histograms of the ratios BMDL~a~:SNCD~0.67~ (BMDLs are based on additional effect) with medians closest to 1 based on all included curves (*n *= 8,456). BMDL, lower confidence limit of the benchmark dose; SNCD, signal-to-noise crossover dose.](EHP408.g005){#f5}

At the median, the SNCD~0.5~ lay between the BMDL~10a~ and the BMDL~15a~ when all curves (*n* = 8,456) were considered ([Figure 4C](#f4){ref-type="fig"}). The BMDL~05a~ was closest to the SNCD~0.5~ for stress response assays; the BMDL~10~ approximated to the SNCD~0.5~ for cytotoxicity assays; and a concentration between the BMDL~15a~ and the BMDL~20a~ corresponded to the SNCD~0.5~ for nuclear receptor assays ([Figure 4C](#f4){ref-type="fig"}).

Effect at the SNCD
------------------

[Figures 6](#f6){ref-type="fig"} and [7](#f7){ref-type="fig"} show the medians, as well as the lower 5th and upper 95th percentiles, for the extra and additional effects at the SNCD, respectively, using all included curves (*n* = 8,456) as the basis. These results indicate that the SNCD~1.0~, SNCD~0.67~, and SNCD~0.5~ corresponded to a median upper bound on the extra effect of 40% (corresponding to the BMDL~40e~), 25% (corresponding to a concentration between BMDL~20e~ and BMDL~30e~), and 18% (corresponding approximately to the BMDL~20e~), respectively ([Figure 6](#f6){ref-type="fig"}). Similar results in [Figure 7](#f7){ref-type="fig"} show that the SNCD~1.0~, SNCD~0.67~, and SNCD~0.5~ corresponded to a median upper bound of the additional effect of 25% (corresponding to the BMDL~25a~), 17% (corresponding to a concentration between the BMDL~15a~ and the BMDL~20a~), and 13% (corresponding to a concentration between the BMDL~10a~ and the BMDL~15a~), respectively. The results illustrated in [Figures 6](#f6){ref-type="fig"} and [7](#f7){ref-type="fig"} are consistent with those presented in [Figures 2](#f2){ref-type="fig"}--[5](#f5){ref-type="fig"}.

![Extra effect at the SNCD. Medians (solid circles) and intervals describing the lower 5th and upper 95th percentiles are shown based on all included curves (*n *= 8,456). Red circles correspond to the upper bound of the effect, and cyan circles correspond to the point estimate of the effect. SNCD, signal-to-noise crossover dose.](EHP408.g006){#f6}

![Additional effect at the SNCD. Medians (solid circles) and intervals describing the lower 5th and upper 95th percentiles are based on all included curves (*n *= 8,456). Red circles correspond to the upper bound of the effect, and cyan circles correspond to the point estimate of the effect. BMDL, lower confidence limit of the benchmark dose; SNCD, signal-to-noise crossover dose.](EHP408.g007){#f7}

Analysis of NTP Duplicates
--------------------------

Chemicals tested in duplicate on the NTP assay plates were analyzed separately to investigate the stability of estimated quantities across duplicates, as well as the result of merging duplicates. Considering curves in classes 1 and 2 ("complete response curve" and "incomplete curve," respectively), on which the overall analysis is based, 320 duplicates were identified (i.e., 640 individual curves). At the median, the BMDL differed between these duplicates by a factor of 1.6--2.2 for BMDLs defined in terms of extra effect and a factor of 1.6--2.0 for BMDLs defined in terms of additional effect: the differences decreased with increasing BMR ([Table 2](#t2){ref-type="table"}). At the median, the SNCD differed between duplicates by a factor of 1.7--1.8, depending on the SNR ([Table 2](#t2){ref-type="table"}). It may be noted that the upper 95th percentile of the BMDL ratio across duplicates was very high at low BMRs, ranging between 100 and 600 depending on the BMR. For other BMDLs, the upper 95th percentile of the ratio of difference between duplicates was in the range of 20- to 40-fold for BMDLs defined in terms of extra effect and 30- to 50-fold for BMDLs defined in terms of additional effect. For the SNCD, the upper 95th percentile of the ratio of difference between duplicates was in the range of 30-fold.

###### 

Comparison of BMDLs and SNCDs for NTP duplicates.

  Type of comparison                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Quantity    Median   5th percentile   95th percentile   *X*^*e*^
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- -------- ---------------- ----------------- ----------
  BMDL ratio between duplicates (extra effect)^*a*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            BMDL~05e~   2.2      1.0              625               ---
  BMDL~10e~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.9         1.0      140              ---               
  BMDL~20e~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.7         1.0      43               ---               
  BMDL~30e~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.6         1.0      26               ---               
  BMDL~40e~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.6         1.0      17               ---               
  BMDL ratio between duplicates (additional effect)^*b*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       BMDL~05a~   2.0      1.0              455               ---
  BMDL~10a~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.7         1.0      104              ---               
  BMDL~15a~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.6         1.0      51               ---               
  BMDL~20a~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.6         1.0      32               ---               
  BMDL~25a~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.6         1.0      29               ---               
  SNCD ratio between duplicates^*c*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           SNCD~1.0~   1.7      1.0              29                ---
  SNCD~0.67~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1.7         1.0      28               ---               
  SNCD~0.5~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.8         1.0      35               ---               
  SNCD~duplicate\ GM~:SNCD~merged~^*d*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        SNCD~1.0~   1.0      0.45             3.1               0.58
  SNCD~0.67~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1.1         0.47     3.0              0.62              
  SNCD~0.5~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.1         0.44     3.1              0.63              
  Notes: BMDL, lower confidence limit of the benchmark dose; GM, geometric mean; NTP, National Toxicology Program; POD, point of departure; SNCD, signal-to-noise crossover dose. The analysis is based on 307 duplicates (614 individual curves). There are a total of 320 NTP duplicates with curves in classes 1 and 2; that is, 320--307 = 13 curves have been excluded from this analysis because they did not show a concentration--response trend according to criteria described in "Concentration--response modeling and estimation of PODs" in the Supplemental Material. The BMDL ratios have been calculated such that they are always \> 1 (max value/min value). ^***a***^Ratio of extra effect BMDLs between duplicates. ^***b***^Ratio of additional effect BMDLs between duplicates. ^***c***^Ratio of SNCDs between duplicates. ^***d***^Ratio of the geometric mean of the SNCD between duplicates (SNCD~duplicate\ GM~) and the corresponding SNCD resulting from analysis of merged duplicates (SNCD~merged~). ^***e***^Fraction of curves for which the ratio is \> 1.                                                           

[Table 2](#t2){ref-type="table"} also provides summary information for the ratio between the geometric mean of the SNCD from separate analysis of duplicates and the SNCD associated with analysis of merged duplicates. At the median, this ratio was \~1; for \~60% of the cases, the ratio was \> 1 ([Table 2](#t2){ref-type="table"}). Overall, the SNCD associated with the analysis of merged duplicates approximated well to the geometric mean of SNCDs from separate analysis of duplicates.

In "Analysis of NTP duplicates" in the Supplemental Material, it is shown that summary results describing the effect at the SNCD for the case of separate analysis of duplicates are very similar to the corresponding results associated with the analysis of merged duplicates, and median values for the effect at the SNCD are also similar to those obtained for the whole database ([Figures 6](#f6){ref-type="fig"} and [7](#f7){ref-type="fig"}; see also Table S1).

Discussion
==========

In this article, we compared two points of departure---the traditional BMDL and the recently proposed SNCD---applied to \> 8,000 high-throughput experimental concentration--response curves generated during Tox21 Phase I ([@r30]). The results from these comparisons showed that the BMDL~40~, BMDL~25~, and BMDL~18~, defined in terms of extra effect, correspond to the SNCD~1.0~, SNCD~0.67~, and SNCD~0.5~, respectively, at the median ([Figure 6](#f6){ref-type="fig"}). Similarly, the BMDL~25~, BMDL~17~, and BMDL~13~, defined in terms of additional effect, correspond to the SNCD~1.0~, SNCD~0.67~, and SNCD~0.5~, respectively, at the median ([Figure 7](#f7){ref-type="fig"}).

Separate analysis of NTP duplicates showed that the difference in BMDLs and SNCDs between duplicates was generally within a factor of 2 at the median ([Table 2](#t2){ref-type="table"}). However, the difference between duplicates was large for a portion of the curves, particularly for BMDLs corresponding to low BMRs (see the upper 95th percentile of the difference between duplicates in [Table 2](#t2){ref-type="table"}). As shown by [@r20], the SNCD decreases with increasing sample size because larger sample size permits the detection of smaller and smaller effects. This phenomenon was, however, not observed in the analysis of the NTP duplicates, possibly because the increase in sample size obtained by merging duplicates was too small (a factor of only 2). The dependence of the SNCD or the BMDL on sample size is typically evaluated theoretically assuming that no (or only a minimal) effect in the mean response occurs: the only effect considered is the effect of more or fewer data for a curve of the same mean response. The analyses in the present paper indicated that the difference between duplicates with respect to the mean response curve appeared to be larger, by a factor in the range of 2, than the change in SNCD that was obtained by merging duplicates: the SNCD based on the analysis of merged duplicates approximated the geometric mean of the SNCD associated with separate analysis of duplicates ([Table 2](#t2){ref-type="table"}).

The findings in this paper depended on the study designs used in the database, which comprised 13--16 concentrations (sometimes fewer after removing outliers) with one observation at each concentration level. SNCDs corresponding to three different SNRs (1, 0.67, and 0.5) were considered. How stringent to be with regard to the selection of the critical SNR that defines the SNCD is a point for discussion even though a critical SNR = 1 may intuitively appear to be most straightforward ("signal" equals "noise"). However, even using the least-stringent criteria (in terms of level of "noise" allowed) corresponding to an SNR of 0.5, BMDLs corresponding to responses in the range of 10% or below appear to be associated with high uncertainty using the SNCD as a reference ([Figures 6](#f6){ref-type="fig"} and [7](#f7){ref-type="fig"}). Similarly, in [Figures 2](#f2){ref-type="fig"} and [4](#f4){ref-type="fig"}, it can be noted that the BMDL~10~ is generally below the SNCDs at the median. The analysis of NTP duplicates from Tox21 Phase I also indicated that at least these HTS data could be very uncertain with respect to estimation of BMDLs corresponding to BMRs of 10% or below because such quantities could differ substantially between individual duplicates ([Table 2](#t2){ref-type="table"}).

For the NTP cancer bioassay data analyzed by [@r20], the BMDL~18~ and BMDL~7.3~, defined in terms of extra risk, corresponded to the SNCD~1.0~ and SNCD~0.67~, respectively, at the median. The corresponding BMDLs in the present study would be the BMDL~40~ and BMDL~25~, based on the extra-effect definition of the BMDL. There are several factors that may explain why the SNCD corresponded to higher BMDLs in the present study than those in the study by [@r20]. First, the data used in the present analysis were continuous in nature, complicating the ability to make a direct comparison between the two studies. In addition, a four-parameter model was used in the present study, whereas three- and two-parameter Hill models were used by [@r20]. The higher level of complexity of the four-parameter Hill model would be expected to result in wider confidence intervals, pushing the SNCD upwards. Furthermore, the SNCD is affected by sample size: whereas the NTP curves evaluated by [@r20] typically included 200 observations (four dose groups, including the control, with 50 animals per group), the curves in the present analysis typically included only 13--16 observations (based on 1 observation per concentration). Moreover, a bootstrap approach was used in the present study for confidence interval estimation, whereas the profile likelihood method was used by [@r20]. In contrast to the analysis by [@r20], the present analysis adjusted the estimate of variance (the likelihood estimator of the variance) to an unbiased estimator (see "Concentration--response modeling and estimation of PODs" in the Supplemental Material) in the process of confidence interval estimation. This adjustment increased the variance (sometimes marginal, depending on the sample size), which increased the SNCD. Additionally, for these reasons, the BMDL:SNCD ratio may be smaller under the applied bootstrap approach than under the profile likelihood method. Further analysis is needed to investigate the impact of model dependence (with respect to the mean response model) of the results associated with this analysis. The relatively large number of concentration levels (generally 13--16) will, however, constrain dose--response models such that they may not assume very different shapes (in the observable region of response). Using normalized data will tend to decrease the variance and therefore decrease the SNCD.

As an example of the use of the SNCD in a risk-assessment context, [@r20] illustrated how an SNCD-based exposure guideline based on low-dose linear extrapolation, using the upper bound on extra risk at the SNCD as a starting point, might be calculated. The SNCD appears consistent with the definition of a POD given in the [@r31] cancer guidelines, which state that a POD "marks the beginning of extrapolation to lower doses." [@r3] described a POD in a way that conceptually resembles the SNCD: their POD was defined "as the point at which the upper 95% confidence limit for the vehicle response intersects the lower 95% confidence limit for the treated response based on parametric assumptions."

The description of the SNCD and the illustration of its potential uses given by [@r20] are statistical in nature. However, it has also been suggested that a POD derived from dose--response modeling should include a toxicological interpretation. For example, EFSA's opinion on the BMD states that the response (benchmark response, BMR) associated with the BMD should be in the range of the data to avoid having to estimate a BMD by extrapolation. EFSA also notes that their default recommendations, which are based on calibration to the NOAEL approach, may be modified based on statistical or toxicological considerations ([@r10]).

Considering both statistical and biological aspects of the POD, [@r4] and [@r21] argued that the SNCD may represent a starting point for low-dose extrapolation when the upper bound on the risk (or effect) at the SNCD is greater than a "target effect level" (or BMR) established based on biological ([@r4]; [@r21]) or risk-management ([@r21]) considerations. In case the SNCD is below the target effect level, the dose associated with that effect may be directly used as a POD ([@r4]).

According to the [@r19] vision for the future of toxicity testing, increasing attention will be redirected towards determining exposure levels that avoid significant perturbations in toxicity pathways. [@r14] introduced the concept of biological pathway activating dose (BPAD) and, as a starting point for the establishment of the BPAD, used the ToxCast^TM^ AC~50~ values (the concentration at 50% of maximum activity) as PODs in their illustration of the BPAD concept. AC~50~ values have also been considered in other analyses of *in vitro* data ([@r3]; [@r28]; [@r33]). As an alternative to using the AC~50~, [@r22] suggested that the dose at which the slope of the S-shaped dose--response curve changes the most per unit log-dose, denoted BMD~T~, may serve as a standardized reference point in the low dose--region for *in vitro* data. The BMD~T~/BMDL~T~, which approximates the BMD~20~/BMDL~20~ using the extra effect definition under the Hill model, was introduced by [@r24] and was suggested as a mathematical definition of a dose within a "transition dose range," as discussed by [@r26]. Derivation of PODs like the BMD~T~ as well as the AC~50~ requires adequate characterization of the S-shaped concentration--response curve (including the asymptotes).

As noted in "Methods," only curves in classes 1 and 2 were considered in this work to support modeling of the full S-shaped curve. Consequently, results from this analysis are limited in this context and do not address the issue of POD derivation for concentration--response curves that are poorly characterized. [@r25] concluded that to improve nonlinear parameter estimation, optimal study designs should be developed, or alternative approaches with reliable performance characteristics should be used to describe concentration--response curves; suggestions that address the latter issue have also been proposed ([@r11]).

It may be questioned whether derivation of PODs for *in vitro* data should involve biological, policy, or risk-management considerations regarding the effect level associated with the POD. At this point, it is unclear if avoiding "significant perturbations in toxicity pathways" would imply that some (presumably small) changes in response might be allowed with regard to the suite of critical *in vitro* end points that would be needed to be evaluated in a future risk-assessment framework ([@r17]). Although conceptually reasonable, the determination of BMRs representing "nonadverse" response levels, or similar, for various end points is a major challenge within the current risk-assessment approach, and, if applicable, such may also be the case for *in vitro* data. An even more complex issue is determination of which changes in biological effect parameters are acceptable in the case of end points that are not adverse and are not the critical effect or its known and immediate precursor. Issues related to this point have also been discussed by [@r6] and [@r22].

It is likely that derivation of PODs from *in vitro* high-throughput screening data will need to rely on standardized approaches, at least as a starting point. Because the use of *in vitro* data significantly increases the amount of concentration--response data that needs to be processed, the use of standardized modeling protocols, including standardized PODs, may be of importance, at least from a practical point of view. [@r34] recently discussed the use of a standardized protocol for BMD analysis that was argued to provide greater transparency and efficiency than current approaches. Their approach was illustrated for traditional animal toxicity data, but the relevance of this type of approach was also suggested to be of particular value in the case of high-throughput *in vitro* testing ([@r34]). [@r29] noted that more efficient risk-assessment approaches are needed owing to the fact that the number of chemicals without toxicity reference values combined with the rate of new chemical development is overwhelming the capacity of the traditional risk-assessment approach. Interestingly, the results of their studies of comparing transcriptional BMD values for the most sensitive pathway with BMD values for the noncancer and cancer apical end points showed a high degree of correlation, suggesting that (for their studied chemicals) transcriptional perturbation did not occur at significantly lower doses than apical responses ([@r29]).

The SNCD may provide a reference level for determining how low a standardized BMD, BMDL, or similar (potency-based) quantity may be selected. For example, in risk-assessment applications where BMDs are derived for several chemicals or end points, a default or screening POD may be chosen such that it is generally not below the SNCD. Based on the present analysis, such a screening level may be lower than the commonly used AC~50~, discussed above, because the AC~50~ (i.e., the BMDL~50~) is higher than all SNCDs at the median ([Figures 6](#f6){ref-type="fig"} and [7](#f7){ref-type="fig"}). Considering the range of SNCDs evaluated, the BMDL~20~ may be more appropriate as a standardized POD in this context (in terms of extra effect, the BMDL~20~ corresponds to a concentration between the SNCD~0.5~ and the SNCD~0.67~ at the median; in terms of additional effect, the BMDL~20~ corresponds to a concentration between SNCD~0.67~ and SNCD~1.0~ at the median) ([Figures 6](#f6){ref-type="fig"} and [7](#f7){ref-type="fig"}). As noted previously, BMDLs associated with BMRs \< 10% generally appear to not be supported from a statistical point of view when using the SNCD as a reference ([Figures 6](#f6){ref-type="fig"} and [7](#f7){ref-type="fig"}). BMRs \< 10% may, however, be supported for individual curves when using the SNCD as a reference.

The SNCD concept may also be used as a starting point for low-dose extrapolation in establishing exposure guidelines corresponding to a given target risk ([@r4]; [@r20], [@r21]) using empirical models of a linear or nonlinear nature. This approach may also be viewed as the application of a curve-specific uncertainty factor to the SNCD, which depends on the risk/effect at the SNCD and the empirical extrapolation model used ([@r20]). It may be noted that, if the dose--response is sublinear, the risk estimate by the SNCD generally decreases as the sample size increases, as discussed by [@r20]. Increasing sample size lowers the SNCD, and under a linear extrapolation approach (drawing a straight line between the upper bound of risk/effect at the SNCD and the background response), the dose corresponding to a given target risk/effect then increases (less conservative) because the slope of the linear model becomes smaller. Although this approach may be appropriate for severe apical end points, the circumstances under which an approach involving low-dose extrapolation would be required in risk assessments based on *in vitro* data remain to be seen.

Conclusion
==========

The NRC vision for the future of toxicity testing suggests that PODs for risk assessments may be increasingly based on *in vitro* HTS data, a notion that has been incorporated into the U.S. EPA's framework for the next generation of risk science. The technical definition of a POD derived from dose--response modeling has stimulated significant discussion within the current risk-assessment paradigm; the present study has extended this discussion to the case of HTS data using a large database comprising HTS experimental concentration--response curves generated during Tox21 Phase I. How the POD for HTS data should be designed to support future risk-assessment applications warrants further discussion. Although end point--specific definitions of the BMD, based on judgment applied on a case-by-case basis, are conceptually appropriate, they may be problematic in practice given the vast amount of data that will be generated through the greatly expanded application of robotically mediated high-throughput *in vitro* testing. Such rich data may require the use of standardized procedures and PODs for practical application and meaningful interpretation. The SNCD may provide a reference level that guides the determination of standardized BMDs, or similar potency-based measures, such that they are not subject to excessive uncertainty. Based on the present database, comprising \> 8,000 HTS curves, such BMDs and BMDLs may need to be associated with a response higher than the standard responses of 5% or 10%. The SNCD may also be of potential use as a starting point for low-dose extrapolation in the process of establishing safe exposure limits.

Supplemental Material
=====================

###### 

Click here for additional data file.
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